PharmAust (ASX:PAA)
Company Profile
PharmAust (ASX:PAA) has changed its name to Neurizon Therapeutics – NUZ (ASX: NUZ).
Below are the previous articles from PharmAust (ASX:PAA):
RELATED STOCKHEAD STORIES
Closing Bell: ASX up but MinRes slumps on lithium downgrade; China stocks also sink
Long Shortz with PharmAust: Sweet incentives for sad disease’s drug development
Health Kick Podcast: PharmAust in the fight against MND and ALS with lead drug monepantel
The Ethical Investor: Falling birth rates propel pets sector, and why ESG investors should tap into it
ASX stocks leading clinical trials in Australia
Closing Bell: ASX choppy as traders sit it out; BPM soars on Mt Gibson gold find
PharmAust seeks orphan drug designation in Europe for monepantel to treat ALS
Morgans sees big upside for PharmAust if monepantel succeeds
PharmAust reports positive interim results of OLE study on monepantel to treat ALS
ASX Health Stocks: Actinogen skyrockets 125pc on antidepressant drug trial results
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
ScoPo’s Powerplays: ASX health stocks up in ‘fairly lacklustre week’
ASX Small Caps Lunch Wrap: The ASX is all red after a night to forget for US tech
